Is Hadlima approved by the FDA for treating ankylosing spondylitis?
Hadlima is a tumor necrosis factor (TNF) blocker approved by the FDA to reduce signs and symptoms in adult patients with moderately to severely active ankylosing spondylitis 2. This medication is indicated to inhibit the progression of structural damage and improve physical function for these patients 2.
What the research says
The FDA approval specifically covers the use of Hadlima for reducing signs and symptoms in adult patients with active ankylosing spondylitis 2. The approval also includes the ability to inhibit structural damage and improve physical function in this patient group 2.
Research indicates that biosimilar versions of TNF inhibitors, which are therapeutically equivalent to the original drugs, are also used for managing ankylosing spondylitis 4. These biosimilars maintain disease control in stable patients and offer cost reductions while showing comparable safety profiles 4.
Other studies focus on specific risks or mechanisms in patients taking these drugs. For instance, research has looked at the risk of sudden sensorineural hearing loss in patients with ankylosing spondylitis who receive adalimumab combined with methotrexate 5. Additionally, broader reviews explore how RNA methylation influences autoimmune conditions like ankylosing spondylitis 3.
What to ask your doctor
- Is Hadlima the right TNF blocker for my specific type of ankylosing spondylitis?
- What are the signs and symptoms I should monitor while taking this medication?
- Are there biosimilar alternatives to Hadlima that might be covered by my insurance?
- What are the potential risks, such as hearing loss, associated with taking adalimumab?
This question is drawn from common patient questions about Rheumatology and answered using cited medical research. We do not provide individualized advice.